OncoMatch/Clinical Trials/NCT04215003
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
Is NCT04215003 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including A and B for breast cancer.
Treatment: A · B · CL4 — This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design, umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Naïve to chemotherapy or hormonal treatments
Cannot have received: hormonal therapy
Naïve to chemotherapy or hormonal treatments
Cannot have received: radiotherapy
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Cannot have received: targeted therapy
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Cannot have received: other clinical trials
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Lab requirements
Blood counts
neutrophil count ≥ 1.5x10^9/L, hemoglobin level ≥ 100 g/L, Platelets ≥ 100 x 10^9/L
Kidney function
serum creatinine ≤110μmol/L, urea nitrogen ≤7.1mmol/L
Liver function
serum aminotransferase (AST) ≤ 60U/L, serum total bilirubin ≤ 2.5 times ULN
Cardiac function
Normal heart function, with normal ECG and LVEF ≥ 55%
Adequate bone marrow function, blood routine examination shows neutrophil count ≥ 1.5x109/L, hemoglobin level ≥ 100 g/L, Platelets ≥ 100 x 109/L Adequate liver and kidney function, serum aminotransferase (AST) ≤ 60U/L, serum total bilirubin ≤ 2.5 times ULN, serum creatinine ≤110μmol/L, urea nitrogen ≤7.1mmol/L ... Normal heart function, with normal ECG and LVEF ≥ 55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04215003 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages